The effect of long-term treatment with granulocyte colony-stimulating factor on hematopoiesis in HIV-infected individuals

TY - JOUR

T1 - The effect of long-term treatment with granulocyte colony-stimulating factor on hematopoiesis in HIV-infected individuals

AU - Nielsen, S D

AU - Sørensen, T U

AU - Aladdin, H

AU - Ersbøll, A K

AU - Mathiesen, L

AU - Ullum, H

AU - Gerstoft, J

AU - Nielsen, J O

AU - Pedersen, Bente Klarlund

PY - 2000/9

Y1 - 2000/9

N2 - This randomized, placebo-controlled trial examine the long-term effect of granulocyte colony-stimulating factor (G-CSF) on absolute numbers of CD34+ progenitor cells and progenitor cell function in human immunodeficiency virus (HIV)-infected patients. G-CSF (300 microg filgrastim) or placebo was given three times weekly for 12 weeks to 30 HIV-infected patients that had been treated with HAART for at least 24 weeks and not yet achieved CD4 counts above 350 CD4+ cells/microl. Blood samples were collected at weeks 0, 2, 4, 8, and 12, and again 12 weeks after termination of the G-CSF treatment. Significant increase in absolute numbers of circulating CD34+ cells was detected in the treatment group (P = 0.006). The function of progenitor cells was examined in vitro using a colony-forming unit (CFU) assay, and increase in the number of CFU/ml was detected (P = 0.005). In order to estimate the effect of G-CSF on in vivo function of progenitors the white-blood count was determined. Significant increase in white-blood count was found (P < 0.001), while hemoglobin and platelet count decreased (P = 0.001 and P = 0.013, respectively). Significant increase in the CD4 count occurred, but correlation between the numbers of progenitors and the CD4 count was not found. These data suggest that G-CSF mainly increases the number and differentiation of myeloid progenitors.

AB - This randomized, placebo-controlled trial examine the long-term effect of granulocyte colony-stimulating factor (G-CSF) on absolute numbers of CD34+ progenitor cells and progenitor cell function in human immunodeficiency virus (HIV)-infected patients. G-CSF (300 microg filgrastim) or placebo was given three times weekly for 12 weeks to 30 HIV-infected patients that had been treated with HAART for at least 24 weeks and not yet achieved CD4 counts above 350 CD4+ cells/microl. Blood samples were collected at weeks 0, 2, 4, 8, and 12, and again 12 weeks after termination of the G-CSF treatment. Significant increase in absolute numbers of circulating CD34+ cells was detected in the treatment group (P = 0.006). The function of progenitor cells was examined in vitro using a colony-forming unit (CFU) assay, and increase in the number of CFU/ml was detected (P = 0.005). In order to estimate the effect of G-CSF on in vivo function of progenitors the white-blood count was determined. Significant increase in white-blood count was found (P < 0.001), while hemoglobin and platelet count decreased (P = 0.001 and P = 0.013, respectively). Significant increase in the CD4 count occurred, but correlation between the numbers of progenitors and the CD4 count was not found. These data suggest that G-CSF mainly increases the number and differentiation of myeloid progenitors.

KW - Anti-HIV Agents

KW - Blood Cell Count

KW - CD4 Lymphocyte Count

KW - Cell Differentiation

KW - Female

KW - Filgrastim

KW - Granulocyte Colony-Stimulating Factor

KW - HIV Infections

KW - Hematopoiesis

KW - Hematopoietic Stem Cell Mobilization

KW - Hemoglobins

KW - Humans

KW - Leukocyte Count

KW - Male

KW - Neutropenia

KW - Platelet Count

KW - Recombinant Proteins

KW - Time Factors

KW - Clinical Trial

KW - Journal Article

KW - Randomized Controlled Trial

KW - Research Support, Non-U.S. Gov't

M3 - Journal article

C2 - 10972907

SN - 0301-6323

VL - 52

SP - 298

EP - 303

JO - Scandinavian Journal of Immunology, Supplement

JF - Scandinavian Journal of Immunology, Supplement

IS - 3

ER -